279 related articles for article (PubMed ID: 37171695)
21. Inhibitors of the protein-protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line.
Yasuda D; Ohe T; Takahashi K; Imamura R; Kojima H; Okabe T; Ichimura Y; Komatsu M; Yamamoto M; Nagano T; Mashino T
Free Radic Res; 2020 Dec; 54(11-12):859-871. PubMed ID: 32075457
[TBL] [Abstract][Full Text] [Related]
22. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
Hu Y; Luo Z; Cai S; Xie Q; Zheng S
Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
[TBL] [Abstract][Full Text] [Related]
23. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
[TBL] [Abstract][Full Text] [Related]
24. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma.
Huang CY; Chen LJ; Chen G; Chao TI; Wang CY
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232407
[TBL] [Abstract][Full Text] [Related]
25. Activation of p62-Keap1-Nrf2 Pathway Protects 6-Hydroxydopamine-Induced Ferroptosis in Dopaminergic Cells.
Sun Y; He L; Wang T; Hua W; Qin H; Wang J; Wang L; Gu W; Li T; Li N; Liu X; Chen F; Tang L
Mol Neurobiol; 2020 Nov; 57(11):4628-4641. PubMed ID: 32770451
[TBL] [Abstract][Full Text] [Related]
26. Ethanol extract of Eclipta prostrata induces multiple myeloma ferroptosis via Keap1/Nrf2/HO-1 axis.
Li W; Yin X; Fu H; Liu J; Weng Z; Mao Q; Zhu L; Fang L; Zhang Z; Ding B; Tong H
Phytomedicine; 2024 Jun; 128():155401. PubMed ID: 38507850
[TBL] [Abstract][Full Text] [Related]
27. Scalp Acupuncture Protects Against Neuronal Ferroptosis by Activating The p62-Keap1-Nrf2 Pathway in Rat Models of Intracranial Haemorrhage.
Li MY; Dai XH; Yu XP; Zou W; Teng W; Liu P; Yu XY; An Q; Wen X
J Mol Neurosci; 2022 Jan; 72(1):82-96. PubMed ID: 34405366
[TBL] [Abstract][Full Text] [Related]
28. Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma.
Sun L; Wang H; Liu Q; Meng F; Zhang J; Li X; Chang S; Li G; Chen F
Oncol Rep; 2023 Mar; 49(3):. PubMed ID: 36734286
[TBL] [Abstract][Full Text] [Related]
29. Icariside II suppresses ferroptosis to protect against MPP
Fan W; Zhou J
Chin J Physiol; 2023; 66(6):437-445. PubMed ID: 38149556
[TBL] [Abstract][Full Text] [Related]
30. DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma.
Chang K; Chen Y; Zhang X; Zhang W; Xu N; Zeng B; Wang Y; Feng T; Dai B; Xu F; Ye D; Wang C
Cancer Res; 2023 Dec; 83(23):3940-3955. PubMed ID: 37713596
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of CISD2 promotes ferroptosis through ferritinophagy-mediated ferritin turnover and regulation of p62-Keap1-NRF2 pathway.
Li Y; Xu B; Ren X; Wang L; Xu Y; Zhao Y; Yang C; Yuan C; Li H; Tong X; Wang Y; Du J
Cell Mol Biol Lett; 2022 Sep; 27(1):81. PubMed ID: 36180832
[TBL] [Abstract][Full Text] [Related]
32. Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation.
Sun J; Zhou C; Zhao Y; Zhang X; Chen W; Zhou Q; Hu B; Gao D; Raatz L; Wang Z; Nelson PJ; Jiang Y; Ren N; Bruns CJ; Zhou H
Redox Biol; 2021 May; 41():101942. PubMed ID: 33770521
[TBL] [Abstract][Full Text] [Related]
33. Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3.
Hu Z; Zhao Y; Li L; Jiang J; Li W; Mang Y; Gao Y; Dong Y; Zhu J; Yang C; Ran J; Li L; Zhang S
Mol Biol Rep; 2023 Aug; 50(8):6399-6413. PubMed ID: 37326750
[TBL] [Abstract][Full Text] [Related]
34. DN200434, an orally available inverse agonist of estrogen-related receptor γ, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma.
Kim DH; Kim MJ; Kim NY; Lee S; Byun JK; Yun JW; Lee J; Jin J; Kim J; Chin J; Cho SJ; Lee IK; Choi YK; Park KG
BMB Rep; 2022 Nov; 55(11):547-552. PubMed ID: 36016501
[TBL] [Abstract][Full Text] [Related]
35. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.
Li X; Li Y; Lian P; Lv Q; Liu F
Hum Exp Toxicol; 2023; 42():9603271221142818. PubMed ID: 36786348
[TBL] [Abstract][Full Text] [Related]
36. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
[No Abstract] [Full Text] [Related]
37. Protocadherin 20 promotes ferroptosis by suppressing the expression of Sirtuin 1 and promoting the acetylation of nuclear factor erythroid 2-related factor 2 in hepatocellular carcinoma.
Jun L; Chen W; Han L; Yanmin L; Qinglei Z; Pengfei Z
Int J Biochem Cell Biol; 2023 Mar; 156():106363. PubMed ID: 36641129
[TBL] [Abstract][Full Text] [Related]
38. Co-Delivery of siNRF2 and Sorafenib by a "Click" Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma.
Tong R; Feng X; Sun J; Ling Z; Wang J; Li S; Yang B; Deng J; He G; Wu J
Small; 2024 May; 20(21):e2307273. PubMed ID: 38102096
[TBL] [Abstract][Full Text] [Related]
39. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway.
Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N
J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108
[TBL] [Abstract][Full Text] [Related]
40. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma.
Iseda N; Itoh S; Toshida K; Tomiyama T; Morinaga A; Shimokawa M; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Yoshizumi T; Mori M
Cancer Sci; 2022 Jul; 113(7):2272-2287. PubMed ID: 35466502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
